| Year |
Citation |
Score |
| 2017 |
Carfagna M, Cannady E, Ryan T, Herman J, Truex L, Narwani K, Sullivan J. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats. Regulatory Toxicology and Pharmacology : Rtp. PMID 29203403 DOI: 10.1016/J.Yrtph.2017.11.020 |
0.317 |
|
| 2017 |
Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM. Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clinical and Translational Science. PMID 28749581 DOI: 10.1111/Cts.12486 |
0.309 |
|
| 2015 |
Cannady EA, Aburub A, Ward C, Hinds C, Czeskis B, Ruterbories K, Suico JG, Royalty J, Ortega D, Pack BW, Begum SL, Annes WF, Lin Q, Small DS. Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 26639670 DOI: 10.1002/Jlcr.3358 |
0.333 |
|
| 2015 |
Genin MJ, Bueno AB, Agejas J, Manninen PR, Bocchinfuso W, Montrose-Rafizadeh C, Cannady E, Jones T, Stille J, Raddad E, Reidy C, Cox A, Michael M, Michael L. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. Journal of Medicinal Chemistry. PMID 26568144 DOI: 10.1021/Acs.Jmedchem.5B01161 |
0.322 |
|
| 2015 |
Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacology Research & Perspectives. 3: e00179. PMID 26516590 DOI: 10.1002/Prp2.179 |
0.379 |
|
| 2015 |
Payne C, Zhang X, Shahri N, Williams W, Cannady E. AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib Annals of the Rheumatic Diseases. 74: 1063.1-1063. DOI: 10.1136/Annrheumdis-2015-Eular.1627 |
0.357 |
|
| 2011 |
Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. Journal of Lipid Research. 52: 2169-76. PMID 21957197 DOI: 10.1194/Jlr.M018069 |
0.357 |
|
| 2007 |
Rajapaksa KS, Cannady EA, Sipes IG, Hoyer PB. Involvement of CYP 2E1 enzyme in ovotoxicity caused by 4-vinylcyclohexene and its metabolites. Toxicology and Applied Pharmacology. 221: 215-21. PMID 17462685 DOI: 10.1016/J.Taap.2007.03.009 |
0.415 |
|
| 2003 |
Cannady EA, Dyer CA, Christian PJ, Sipes IG, Hoyer PB. Expression and activity of cytochromes P450 2E1, 2A, and 2B in the mouse ovary: the effect of 4-vinylcyclohexene and its diepoxide metabolite. Toxicological Sciences : An Official Journal of the Society of Toxicology. 73: 423-30. PMID 12700394 DOI: 10.1093/Toxsci/Kfg077 |
0.439 |
|
| 2002 |
Cannady EA, Dyer CA, Christian PJ, Sipes IG, Hoyer PB. Expression and activity of microsomal epoxide hydrolase in follicles isolated from mouse ovaries. Toxicological Sciences : An Official Journal of the Society of Toxicology. 68: 24-31. PMID 12075107 DOI: 10.1093/Toxsci/68.1.24 |
0.419 |
|
| 2001 |
Hoyer PB, Cannady EA, Kroeger NA, Sipes IG. Mechanisms of ovotoxicity induced by environmental chemicals: 4-vinylcyclohexene diepoxide as a model chemical. Advances in Experimental Medicine and Biology. 500: 73-81. PMID 11765019 DOI: 10.1007/978-1-4615-0667-6_8 |
0.334 |
|
| Show low-probability matches. |